Hey Snackers,
Is the bull market back? Offbeat indicators like the hemline index (reflecting the length of women’s skirts) or the thickness of former Fed Chair Alan Greenspan’s briefcase have been trotted out as ways to track financial sentiment. We’re adding the necktie indicator to that list. As Morgan Stanley analyst Betsy Graseck observed, bank executives are ditching their ties, which could be a positive signal for the market.
US stocks stumbled on Tuesday after Monday’s more constructive tone on the conflict in the Middle East evaporated by the night, with US President Donald Trump telling Americans to evacuate Tehran last night and calling for Iran’s “UNCONDITIONAL SURRENDER” today. Oil prices headed higher while the S&P 500 ended down 0.8% and the Nasdaq 100 and Russell 2000 gave back 1%.
Consumer discretionary and healthcare stocks fared the worst, with the latter seeing weakness linked to reports that the Trump administration is looking to curb pharma ads. Every S&P 500 sector ETF finished in the red outside of energy, thanks to the aforementioned rally in crude prices.
Markets are closed tomorrow for Juneteenth, but we’ll be back in your inbox on Friday.
A company that nobody’s heard of and doesn’t make any money is up 56,000% this year
It’s comforting to think of markets as a ruthlessly efficient and highly coherent space, an arena where truth is determined through broad access to millions of minds that — through a form of competitive consensus — methodically value the individual firms that constitute a global market. An ecosystem of global commerce that, through compassionless mercantile interest, can appropriately and of course systematically assign a price that we can all agree on.
Comforting, but wrong. Because sometimes, you get Regencell Bioscience.
Regencell Bioscience, a Hong Kong-based herbal medicine company that generates no revenue, has skyrocketed in value amid a rally triggered by a 38-for-1 stock split.
The company, still in its research and development phase, is developing herbal medicine treatments for ADHD and autism.
So far it has only bled money, and generated none.
It’s up about 700% in the past month and more than 56,000% this year, as of Tuesday afternoon.
While short sellers might be scrambling, Regencell’s CEO, Yat-Gai Au, has amassed a $26 billion fortune, Bloomberg reports.
The Takeaway
The company’s short interest as a percentage of float is 94.81%, suggesting somebody is getting squeezed. When that happens, short sellers often rush to buy back their shares, creating demand, which pushes up the share price.
Investment Offering Closing Tomorrow: Stanford StartX Company Raises $14M to Disrupt $8.24B Cardiac Monitor Market
Fresh off clinical testing in the EU and the US, Future Cardia is building an implantable cardiac monitor designed to transform how we detect and manage heart disease — the US’s #1 killer.
🚨 With 39 successful implants and 60,000+ hours of real-world heart data, this startup isn’t theory — it’s action.
🔬Accelerated by Stanford StartX
🏥 Incubated by Johnson & Johnson’s JLABS
👥Team with 200+ years of combined med-tech experience (Medtronic, Boston Scientific, Stanford)
⬜️$14M+ raised from 10,000+ investors across all offerings
⏳Offering Closes Tomorrow.
They’re targeting a $8.24B+ market1 with tech that could change lives.
Nice solar business you got there. Shame if something happened to it.
Details about the Senate’s version of the federal spending bill are coming to light, and new information about how the bill will handle tax credits related to green energy have sent companies in the space spiraling.
Shares of beaten-down hydrogen fuel cell company Plug Power have tumbled almost 18%.
Solar stocks were crushed, with shares of Enphase Energy down 24%, First Solar down 18%, and SolarEdge down 32%.
Analysts say that while the new Senate proposal is clearly a negative for renewable energy names, it is a “significant improvement” from how things looked in the House. Senate Republicans are hoping to move fast to pass the bill before the Fourth of July.
The Senate’s bill would end the green hydrogen production credit at the end of this year. That incentive program, established under the Biden administration’s Inflation Reduction Act, provided up to $3 per kilogram of clean hydrogen produced. According to Plug filings, the credit allowed hydrogen power to be cost competitive with fossil fuels.
The Takeaway
This is a bit unexpected. For instance, Plug Power CEO Andy Marsh told Sherwood News in late February that “We don’t expect that Congress — and Congress, remember, is who decides this — is going to make any changes to the 45V.” Should the bill advance, it appears that was incorrect.
Tinder is trying everything to return to growth, including bringing back a “Double Date” feature
Tinder’s new feature allows pairs of users to match with other pairs... betting on a hypothesis that “dating is better with friends” to boost the platform’s falling user numbers. It didn’t work in 2016, but here’s why they think it’ll work in 2025.
Offering Closing Tomorrow: Invest In A Company Aiming to Disrupt $8.24B Cardiac Monitor Market
Fresh off clinical testing in the EU and US, Future Cardia is building an implantable cardiac monitor designed to transform how we detect and manage heart disease, the world’s #1 killer.
39 successful implants and 60,000+ hours of real-world heart data
$14M+ raised from 10,000+ investors across all offerings
Offering Closes June 19.
Future Cardia is targeting a $8.24B+ market1 with tech that could change lives. Invest now.2
Which 31-year-old website is still one of the most visited websites in America?
Yesterday’s Big Daily Movers
Verve Therapeutics rose more than 81% after Eli Lilly announced it would buy the gene-editing biotech company
JetBlue dipped after CEO Joanna Geraghty informed staff that the carrier would be implementing further cost cuts
Ad companies like WPP and Omnicom fell after reports of a coming pharma ad crackdown and Meta’s AI-made ads
T-Mobile sank after SoftBank dumped $4.9 billion of its stock in the telecom giant
What else we’re Snackin’
Things are not going well for the OpenAI and Microsoft partnership, as the two argue over the size of Microsoft’s eventual stake
Cantor initiated coverage of three solana companies, saying SOL is “overlooked”
Watch out DeepSeek: another Chinese startup is saying it outperforms its AI
The Trump administration is drafting a policy that would make it harder for drugmakers to advertise directly to consumers
Tesla is pausing production (again) at its Texas Gigafactory for… maintenance?
With 39 successful implants and 60,000+ hours of real-world heart data, Future Cardia is building an implantable cardiac monitor designed to transform how we detect and manage heart disease. You can invest today.2
Wednesday
Fed rate decision
May housing starts and building permits
1 The Cardiac Monitoring Market was valued at $8.24 billion in 2024. See the article at Business Wire for more information.
This product is not yet available for purchase and requires review and clearance before being marketed or sold.
2 Please read the offering circular and related risks here. This is a paid advertisement for Future Cardia’s Regulation CF Offering. This Reg CF offering is made available through StartEngine Primary, LLC, member FINRA/SIPC.
In addition, as described in the Offering Circular, the Company retains the right to continue the offering beyond the Termination Date, in its sole discretion.
Investing in private company securities is not suitable for all investors because it is highly speculative and involves a high degree of risk. It should only be considered a long-term investment. You must be prepared to withstand a total loss of your investment. Private company securities are also highly illiquid, and there is no guarantee that a market will develop for such securities.